Objective. To develop and validate a modification of SLEDAI-2K to accurately describe disease activity while accounting for glucocorticoid (GC) doses.
Introduction
The SLEDAI is a global disease activity measure that was initially developed in 1985 [1] , with an updated version, SLEDAI-2000 (SLEDAI-2K), introduced in 2002 [2] . SLEDAI-2K's good psychometric properties and low burden of administration and scoring have made it one of the most commonly used disease activity indices in research [24] and clinical trials [5] . However, SLEDAI-2K does not account for the severity within each descriptor, nor for glucocorticoid (GC) dose, and GC is always an important factor to account for in observational studies and the majority of lupus trials [57] evaluating new drugs in the context of standard of care (SoC) therapy, which includes GC. Thus, there is an unmet need to develop a disease activity instrument that incorporates GC dose into the disease activity measure.
In this study we describe the development of a modification of SLEDAI-2K, SLEDAI-2K GC (SLEDAI-2KG), to accurately describe disease activity while accounting for GC doses. We further compared the performance of SLEDAI-2K and SLEDAI-2KG in identifying responders in response to standard of care therapy.
Methods
Phase 1 focused on the identification of scenarios of real patients to derive weighted scores for GC dose. Phase 2 focused on the development of SLEDAI-2KG (derivation of an equation to explain the link between SLEDAI-2K and GC doses), and phase 3 focused on SLEDAI-2KG validation.
Phase 1: identification of scenarios with a spectrum of organ involvement taking different GC doses The scenarios were of real patients followed prospectively at the University of Toronto Lupus Clinic in the past 20 years (1400 patients and 29 577 visits). Adult patients at the lupus clinic are >18 years of age with a diagnosis of SLE based on four or more ACR criteria or three ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy [8] . The standard protocol at each visit includes: complete history, including demographics and therapy, physical examination and laboratory evaluation. Patients attend the lupus clinic at 26 month intervals regardless of the state of activity of their lupus. Disease activity is measured at each visit by SLEDAI-2K 30 days [2, 9] .
The collection, storage and use of the clinical and laboratory data on the patients at the Centre are conducted in accordance with the Declaration of Helsinki and are approved by the Research Ethics Board of the University Health Network, Toronto, Canada. All patients sign an informed consent (REB#11-0397-AE).
To ensure that scenarios include a spectrum of organ systems manifestation and a full range of GC doses, two data sampling approaches were utilized as follows.
The 15 most common organ involvement combinations in the database were identified (SLEDAI-2K includes nine organ systems and 24 descriptors). We identified the median and 25th and 75th quartile of GC (mg/day) doses in each combination and randomly selected two scenarios at median and one each at the 25th and 75th quartile from the 13 most common combinations of SLEDAI-2K organ involvements. An additional seven scenarios with low complement or anti-ds DNA antibodies alone and scenarios with SLEDAI-2K of 0 were added. This resulted in 59 scenarios, exceeding the minimum sample size calculation required according to the formulas for reliability analysis presented by Streiner et al. [10] .
Patients from the entire database were grouped into eight categories based on a range of GC doses (5, 10, 15, 20, 30, 40 , 50 and 60 mg/day) and 10 patients (10 most common SLEDAI-2K organ combinations) were selected randomly from each GC dose level. This approach generated an additional 80 scenarios. An additional 11 scenarios were added with a SLEDAI-2K score of 0 and low complement or anti-ds DNA, which resulted in a total of 91 scenarios. Thus from the two sampling approaches 150 scenarios were generated. Scenarios included information on patient SLEDAI-2K scores, organ involvement by SLEDAI-2K and GC doses. In this phase, the physician global assessment (PGA) was used to discern the relationship between an increasing GC dose and the SLEDAI-2K score. First, three rheumatologists (Z.T., D.D.G. and M.B.U.) ranked disease activity of patient scenarios using PGA (Likert scale 0: not active; scale 7: most active) [11] which was considered the gold standard. Raters were provided with the SLEDAI-2K total score, individual organ involvement and GC dose. Raters were instructed to account for GC dose while rating disease activity on the PGA. Second, an equation that explained the association between SLEDAI-2K and GC doses was derived.
Phase 3: comparison of SLEDAI-2KG and SLEDAI-2K in identifying responders
Patients seen between January 2011 and 2014, at the University of Toronto Lupus Clinic, with active disease (SLEDAI-2K 5 6) and on prednisone 510 mg/day, and with follow-up visits within 524 months were studied. SoC treatment was determined based on the judgement of the treating rheumatologist. Response to SoC therapy, at first follow-up visit, was assessed by SLEDAI-2K and SLEDAI-2KG. Responders were defined based on the decrease in SLEDAI-2K and SLEDAI-2KG score by 54. The performance of SLEDAI-2K and SLEDAI-2KG was also compared using different cut-off points: 5, 6 and 7.
Analysis
Phase 1. The sample size calculation of needed scenarios was based on the assumption of reliability [intra-class correlation coefficient (ICC)] 50.80 with a standard error of 0.05 and three raters. The required minimum was 46 scenarios.
Phase 2. The Shrout and Fleiss [12] ICC (2, k) was calculated to examine the agreement among three raters. The ICC and the 95% CI calculation was based on the bootstrap method by re-sampling 1000 times with replacement; an ICC >0.85 reflects good agreement [10, 12, 13] .
Derivation of the equation for the new index (SLEDAI-2KG). In preparation for the derivation of the equation, it was important to study the association between GC doses and disease activity score by SLEDAI-2K. First, we evaluated the relationship between GC doses and PGA for different individual SLEDAI-2K levels, and second, we combined all SLEDAI-2K levels in one plot. This allowed us to conclude that the relationship between GC doses and PGA is quadratic (plots are not shown). The relationship among the three components (SLEDAI-2K, PGA and GC doses) is illustrated in a three dimensional histogram ( Fig. 1) . A quadratic linear regression model was created (model 1) to describe the relationship between PGA and GC doses. We also tried a cubic term of GC doses but the regression coefficient of that term was minimal and thus it was neglected. The final model encompassed the linear and the quadratic terms.
The relationship between PGA and SLEDAI-2K was linear and therefore a linear model was created between PGA and SLEDAI-2K (model 2). The last step was to replace the independent parameter of PGA in model 2 with the https://academic.oup.com/rheumatology relationship we obtained in model 1. The final predicted weighted GC dose score is:
Phase 3. Descriptive statistics were used in the analysis.
Results

Phase 1: identification of scenarios
Both approaches yielded 150 visits with different organ involvement (Table 1 ) on a range of GC doses (Table 2) . A three-dimensional histogram that was plotted to illustrate the relation between SLEDAI-2K score (x-axis), GC dose (y-axis) and Likert scale (z-axis) (Fig. 1) demonstrated that PGA was at a high level (active disease reflected by the height of bars) with high SLEDAI-2K scores or with higher doses of GC (Fig. 1) .
The weighted scores of GC doses were derived from equations above. The derived equation between GC and the new SLEDAI-2KG score is as follows:
A simplified table was created to dispay the weighted scores for different GC doses. All SLEDAI-2KG scores were rounded to the nearest integer. For instance, SLEDAI-2K of 6 in a patient on 10 mg/day of GC results in SLEDAI-2KG of 9 ( Table 3 ). The weighted GC dose score plateaued when the GC dose reached 537.5 mg/day. Therefore, a score of 8 was assigned to GC doses 537.5 mg/day (supplementary Fig. S1 , available at Rheumatology online). Table 4 shows the newly developed index, SLEDAI-2KG, which includes the same 24 descriptors of SLEDAI-2K, in addition to the new descriptor, GC, and its scoring approach. Table S1 , available at Rheumatology online. SLEDAI-2KG identified more responders at 6 months (93% vs 84%) and at 12 months (92% vs 76%) compared with SLEDAI-2K by cut-off of 4. SLEDAI-2KG also identified more responders with cut-off points 5, 6 and 7 (Table 5 ).
Discussion
In this study, we presented the development of a modification of SLEDAI-2K, SLEDAI-2KG, able to describe disease activity while accounting for GC doses. Phase 1 resulted in the identification of 150 case scenarios of real patients, with a spectrum of organ systems manifestations and a wide range of GC doses, which were scored by rheumatologists and resulted in the derivation of weighted scores of different GC doses. Phase 2 resulted in the derivation of an equation for SLEDAI-2KG that accounts for SLEDAI-2K score and the weighted score of different GC doses. The weighted score of GC doses was further simplified in a Table 3 (First and second columns) that summarizes the GC dose weighted scores for different cut-offs of GC doses. The newly developed index, SLEDAI-2KG, was superior to SLEDAI-2K in identifying responders at 6 and 12 months. The assessment of lupus disease activity can be very challenging and SLEDAI-2K standardized this assessment and quantified disease activity [2, 9] . The wide use of SLEDAI-2K was a result of its good psychometric properties [2, 9, 14] , acceptable administration burden and simple scoring [15] . While a complete history, physical examination and laboratory results are required, the scoring of SLEDAI-2K is simple and additive. We also ensured that the new index, SLEDAI-2KG, conveys a low administration burden and a simple scoring system. Table 3 demonstrated the simple and intuitive steps required for the derivation of SLEDAI-2KG scores. Indeed, it requires only the SLEDAI-2K scores and the dose of GC, which becomes the final descriptor in the activity index as reflected in Table 4 . Glucocorticoid weighted score is derived only if glucocorticoid is used to treat lupus. If the patient is on glucocorticoid for asthma, in the context of renal transplant, etc. the weighted GC score should be 0. SLEDAI-2KG: SLE Disease Activity Index Glucocorticosteroid Index; CVA: cerebrovascular accident; CH 50: hemolytic complement; (C3) and C4: complement. The new modification (SLEDAI-2KG) adds another variable (weighted score for GC dose), which will allow the physician to more accurately gauge the severity of activity within a descriptor of SLEDAI-2K. For example a patient with thrombocytopenia of 80 000 and another at 10 000 will both be scored as 1 on SLEDAI-2K, but will be treated with different doses of prednisone. This will be accounted for with the new GC dose descriptor. This concept is applicable to all 24 descriptors of SLEDAI-2KG. The management of nephrotic proteinuria in lupus nephritis (e.g. proteinuria of 4 g/day) often requires a larger dose of prednisone compared with the management of subnephrotic proteinuria (e.g. proteinuria of 1 g/day) where a lower dose of prednisone might be sufficient. SLEDAI-2KG accounts for prednisone dose and differentiates between these scenarios [e.g. proteinuria (weighted score of 4) and prednisone 40 mg/day (weighted score of 7) will result in a total score of 11 compared with proteinuria (weighted score of 4) and prednisone 15 mg/day (weighted score of 4) that will result in a total score of 8]. In this example, a higher total score of 11 was achieved in the patient with nephrotic proteinuria compared with a total score of 8 in the patient with subnephrotic proteinuria. Clearly SLEDAI-2KG helps to reflect the severity of disease activity, within each descriptor, while accounting for GC doses, rather than describing the descriptor as present or absent as with SLEDAI-2K. Thus a reduction in GC dose signifies a response or a signal of decrease in the severity of the clinical manifestation or its complete resolution. The level required to achieve disease improvement as opposed to disease quiescence based on the new index will be determined in future studies.
SLEDAI-2K is widely utilized in research settings, clinical trials and to a lesser extent in clinics. The use of SLEDAI-2KG will enable researchers to study the effect of disease activity combined with GC dose in long term observational studies looking at outcomes in SLE and at organ damage where GC dose may be an important factor to account for in patients with different demographics and in patients from different cohorts. In the past decade we have witnessed a plethora of clinical trials for potential new drugs in lupus. The concept of SLEDAI-2KG is novel and it might enhance the analyses in clinical trials to differentiate between responders on minimal and large doses of GC. In clinical trials where GC doses are fixed, the role of this new index, SLEDAI-2KG, might be limited and future analyses will further elaborate on this hypothesis.
In our scenarios we only chose patients taking up to a maximum of 60 mg/day of prednisone. However, in the derivation of this new index, it was clear that the GC dose weighted score plateaued when GC dose reached 537.5 mg/day. Thus, the quadratic relationship between GC doses and equivalent SLEDAI-2K scores resulted in the assignment of a score of 8 to GC doses 537.5 mg/ day. Furthermore, in our clinic <8% of patients received GC treatment higher than 60 mg/day. Similarly, in drug trials patients taking GC doses of 60 mg/day or more are usually excluded. This also ensured that GC dose was not assigned a value greater than any other SLEDAI-2K descriptor.
In conclusion, we developed a novel modification of SLEDAI-2K, SLEDAI-2KG, that describes disease activity while accounting for GC dose. Furthermore, we showed that SLEDAI-2KG improves the ability to identify responders compared with SLEDAI-2K in outcome studies. Ongoing prospective data collection at the University of Toronto Lupus Clinic is being conducted to further validate SLEDAI-2KG compared with different constructs including PGA on a visual analogue scale and Likert scale. In addition, an international external validation phase will be conducted on SLEDAI-2KG.
